Sumati Gupta, MD
Sumati Gupta, MD, is an Assistant Professor in the Division of Oncology, Department of Medicine, at the University of Utah‘s Huntsman Cancer Institute.
Dr. Gupta is a specialist in adult medical oncology and her main areas of interest include Genitourinary Cancer (bladder, kidney, prostate, and testicular cancer). Dr. Gupta is the Co-Director of the Geriatric Oncology clinic at the University of Utah.
Dr. Gupta earned her medical degree from the University of Mumbai (KEM) in India. She then completed a residency in Internal Medicine at SUNY Stony Brook, East Meadow program at Nassau University Medical Center. Dr. Gupta then completed a fellowship in Geriatrics at Baylor College of Medicine in Houston, Texas. She practiced at the University of Utah Clinics for 10 years in Primary Care and Geriatrics. Dr. Gupta then completed a fellowship in Medical Oncology at the University of Utah and the Huntsman Cancer Institute.
Dr. Gupta is a member of the Genitourinary Cancers and Experimental Therapeutics program at the Huntsman Cancer Institute. Dr. Gupta is a clinical investigator and treats patients in clinical trials at Huntsman Cancer Institute. Dr. Gupta’s main areas of research are clinical and translational aspects of bladder cancer. She investigates mechanisms of treatment resistance to translate to more effective treatment of cancer. Dr. Gupta is also involved in individual and population-based studies to identify genetic and environmental risks of bladder cancer.
Dr. Gupta is a member of the University of Utah’s Data Safety Monitoring and Compliance committee. She also holds a part-time appointment at the Salt Lake City Veteran Administration hospital where she treats veterans, teaches residents, and provides clinical expertise in Genitourinary Cancers.
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:QEDDate added:09/20/2022Date updated:09/20/2022
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Bristol Myers SquibbDate added:09/20/2022Date updated:09/20/2022
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:IncyteDate added:09/20/2022Date updated:09/20/2022
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:RexahnDate added:09/20/2022Date updated:09/20/2022
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:NovartisDate added:09/20/2022Date updated:09/20/2022
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:LSKDate added:09/20/2022Date updated:09/20/2022
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:AcrotechDate added:09/20/2022Date updated:09/20/2022
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Astra ZenecaDate added:09/20/2022Date updated:09/20/2022
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:ClovisDate added:09/20/2022Date updated:09/20/2022
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:MerckDate added:09/20/2022Date updated:09/20/2022